Spend on cancer per patient in England 2006 - 2007
£8,262
Compare this with other PCTs: highest amount spent was £17,028, lowest was £5,182, and average PCT spend per cancer patient was £8,437.
Exceptional funding for cancer treatment
The following information was requested from the PCT in 2008 under the Freedom of Information Act.
Written protocols
The PCT has a policy on the management of Non-Contractual Treatments (NCT). The policy is used to assess funding of care services which are outside of service agreements and contracts, where cases need assessment against existing policies and where non-mainstream treatments are proposed.
Membership of NCT Panel
- Assistant Director of Finance
- Lay Board Member
- Prescribing Lead
- Assistant Director of Public Health
- Health Improvement Manager
- Project Manager - PCT Provider Services Commissioning
- Commissioning Manager
- Two Assistant Directors of Commissioning (Joint Chairs)
- Assistant Director of Public Health - Clinical Effectiveness
- Library and Knowledge Services
Cancer treatments funded by PCT following exceptional requests
From October 2006 to 09 June 2008, the PCT's NCT Panel approved 46 cancer treatment requests. These were:
- Alimta - 1
- Allograft bone marrow transplant - 2
- Ovarian carcinoma assessment - 1
- Autologous bone marrow transplant - 8
- Brachytherapy - 1
- Clofarabine and Daunoxome - 1
- Dasatinib - 1
- Extracorporeal photochemotherapy - 1
- High intensity focused ultrasound - 2
- Hyberbaric oxygen treatment - 2
- I-mlbg - 1
- Interferon - 1
- Matched unrelated donor transplant - 6
- Pemetrexed -2
- PET scan - 4
- Proton beam irradiation - 2
- Radio frequency ablation - 1
- Rituximab - 1
- Stem cell harvest - 1
- Stem cell transplant - 3
- Stereotactic radiosurgery - 2
- Temozolomide - 2
Cancer treatments not funded by PCT following exceptional requests
Cancer treatments not approved by the PCT's NCT panel from October 2006 to 09 June 2008 were:
- 5 Azacytidine - 1
- Alimta - 5
- Avastin - 1
- Bortezomib - 4
- Cetuximab - 3
- Cetuximab plus Irinotecan -1
- Matched unrelated donor transplant - 6
- Neoadjuvant temozolomide - 1
- Radio frequency ablation - 1
- Sorafenib - 1
- Stereotactic radiosurgery - 2
- Sunitinib - 9
- Tarceva - 2
- Temozolomide -1
